Endonovo Therapeutics (ENDV) Stock Chart & Stock Price History $0.0002 0.00 (0.00%) As of 08/15/2025 03:20 PM Eastern Add Compare Share Share Chart Stock AnalysisChartSEC FilingsShort InterestBuy This Stock Endonovo Therapeutics Stock Price Performance The Endonovo Therapeutics (ENDV) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 80.00%, with a year-to-date return of -50.00%. In the past month, the stock has increased 100.00%, reflecting recent market activity. As of the latest close, Endonovo Therapeutics traded at $0.00 with a market cap of $241 thousand and volume of 100 shares. Five years ago, the stock traded at $0.11, representing a 99.81% decrease over that period. At the time, it had a market cap of $105.27 million and a volume of 38,717 shares. Receive ENDV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance0.00%1 Month Performance+100.00%3 Month Performance0.00%Year-To-Date Performance-50.00%1 Year Performance-80.00%5 Year Performance-99.81% ENDV Stock Chart for Saturday, August, 16, 2025 ENDV Chart by TradingView Endonovo Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/15/2025$0.00$0.00$0.00$0.00100 shs$241,000.0008/14/2025$0.00$0.00$0.00$0.00585,050 shs$241,000.0008/13/2025$0.00$0.00$0.00$0.001.35 million shs$241,000.0008/12/2025$0.00$0.00$0.00$0.00601,500 shs$241,000.0008/11/2025$0.00$0.00+100.00%$0.00$0.0026.20 million shs$241,000.0008/08/2025$0.00$0.00$0.00$0.00100.50 million shs$121,000.0008/07/2025$0.00$0.00$0.00$0.002.31 million shs$121,000.0008/06/2025$0.00$0.00$0.00$0.002,050 shs$121,000.0008/05/2025$0.00$0.00$0.00$0.006.47 million shs$121,000.0008/04/2025$0.00$0.00-50.00%$0.00$0.006,002 shs$121,000.00 Get the Latest News and Ratings for ENDV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/01/2025$0.00$0.00$0.00$0.00109,000 shs$241,000.0007/31/2025$0.00$0.00$0.00$0.00109,000 shs$241,000.0007/30/2025$0.00$0.00$0.00$0.00328,164 shs$241,000.0007/29/2025$0.00$0.00$0.00$0.00606,044 shs$241,000.0007/28/2025$0.00$0.00$0.00$0.005.13 million shs$241,000.0007/25/2025$0.00$0.00+100.00%$0.00$0.0040.40 million shs$241,000.0007/24/2025$0.00$0.00$0.00$0.0047.90 million shs$121,000.0007/23/2025$0.00$0.00-66.67%$0.00$0.0050.17 million shs$121,000.0007/22/2025$0.00$0.00$0.00$0.001,500 shs$362,000.0007/21/2025$0.00$0.00+50.00%$0.00$0.00371,654 shs$362,000.0007/18/2025$0.00$0.00$0.00$0.003.67 million shs$241,000.0007/17/2025$0.00$0.00+100.00%$0.00$0.001.25 million shs$241,000.0007/16/2025$0.00$0.00$0.00$0.001,500 shs$121,000.0007/15/2025$0.00$0.00$0.00$0.0050,600 shs$121,000.00 Related Companies TTOO Stock Chart IONM Stock Chart HSDT Stock Chart INLB Stock Chart MAGAA Stock Chart SDCCQ Stock Chart GMVDF Stock Chart HYBT Stock Chart RGIN Stock Chart VRAYQ Stock Chart Receive ENDV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:ENDV) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access